HOME >> MEDICINE >> NEWS
Study finds new designer drug is potent treatment for chronic myelogenous leukemia

BOSTON--A laboratory study led by researchers at Dana-Farber Cancer Institute has shown that a potent and highly selective therapy for chronic myelogenous leukemia (CML) may ultimately be more effective than Gleevec, the current standard of care. The researchers report in the February issue of Cancer Cell that the new compound, AMN107, is about 20 times more potent than Gleevec and is effective in treating Gleevec-resistant disease in model systems. Discovered by and in development with Novartis Pharma AG, AMN107 is a small molecule tyrosine kinase inhibitor.

"While Gleevec represents a major treatment advance for CML approximately 95 percent of patients treated with Gleevec achieve remission there clearly is a need for therapies that produce longer remissions, are active against advanced disease, and can be used when Gleevec loses effectiveness," says Dana-Farber's James Griffin, MD, senior author of the study.

Gleevec shuts down CML by blocking the function of Bcr-Abl, the abnormal tyrosine kinase protein in the leukemic cells that causes them to grow too quickly. However, it does not bind very tightly to this protein, and patients can develop a resistant type of Bcr-Abl that no longer binds to Gleevec at all.

Using rational drug design to circumvent these shortcomings, researchers at Novartis determined the crystal structure of Bcr-Abl, and then constructed compounds that would lock into the receptor more securely than Gleevec. Investigators at Dana-Farber tested the new compounds to measure their effectiveness against CML in laboratory cell cultures and mice with the disease.

Data from the study published in Cancer Cell showed that in experiments with laboratory samples of CML cells, AMN107 killed the cells more effectively than Gleevec. In follow-up studies with mice with a human form of CML, AMN107 produced lengthier remissions than Gleevec and triggered remissions in animals in which the disease had become resistant to Gl
'"/>

Contact: Bill Schaller
617-632-4090
Dana-Farber Cancer Institute
18-Feb-2005


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... ... July 17, 2019 , ... It took just several small incisions ... MD, to relieve pressure on the nerves under Amber Walck’s scalp, and suddenly her ... turned 30 last year, her debilitating headaches began without warning. About 39 million ...
(Date:7/17/2019)... ... ... A new study led by researchers at the University of Pittsburgh and published ... the first time that New York’s sepsis protocols are directly responsible for the significant ... infection. It kills more than 275,000 Americans each year and leaves hundreds of thousands ...
(Date:7/13/2019)... ... 2019 , ... Dr. Rupa Jolly, dentist and wife of Dr. Tarun Jolly ... Most Influential New Orleanians in 2019. She joins more than 20 other locals on ... an impact on the New Orleans community. , Combining their backgrounds in science and ...
(Date:7/13/2019)... (PRWEB) , ... July 12, 2019 , ... ... MyBioGate and CUBIO Innovation Center , sponsored by Hangzhou Investment Promotion ... Hotel on June 2, 2019. , The conference attracted Fosun Pharmaceuticals, WuXi Biologics, ...
(Date:7/11/2019)... ... July 11, 2019 , ... The ... resources with a range of features to further advance their mission of delivering ... in manufacturing quality medicines for patients worldwide. The latest additions include a new ...
Breaking Medicine News(10 mins):
(Date:7/11/2019)... ... July 11, 2019 , ... Healthcare Information ... leading provider of enterprise content management solutions, will exhibit at the 2019 Indiana ... to July 19. , Conference attendees are encouraged to stop by booth ...
(Date:7/11/2019)... ATLANTA (PRWEB) , ... July 11, 2019 , ... ... practice in the Southeast– rank among Castle Connolly’s Top Doctors. All of these ... than 40 percent of the physicians in the publication’s urology category and all ...
(Date:7/10/2019)... ... 10, 2019 , ... Physicians for Informed Consent (PIC) sent ... hundreds of its doctor and scientist members out of concern that some legislators, ... to vaccination and labeling them as “fraudulent.” , The letter explains how the ...
Breaking Medicine Technology:
Cached News: